Swedish Orphan Biovitrum AB: Sobi and Selecta Biosciences announce completion of enrolment in DISSOLVE Phase 3 study evaluating SEL-212 for chronic refractory gout

STOCKHOLM, Dec. 1, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced the completion of enrolment for DISSOLVE

Related Keywords

Stockholm ,Sweden ,China ,Boston ,Massachusetts ,United States ,Russia ,America ,Carsten Brunn ,Clin Hypertens ,Brittany Leigh ,Bruce Mackle ,Selecta Biosciences ,Selecta Imm ,Guido Oelkers ,Lifesci Advisors ,Lifesci Communications ,Selecta Biosciences Inc ,Sobi Investor Relations Team ,Nasdaq ,Chief Executive Officer ,Randomized Double Blind ,Placebo Controlled Study ,Gout Refractory ,Conventional Therapy ,Greater Boston ,North America ,Middle East ,Sobi Media ,Sci Advisors ,Sci Communications ,Swedish ,Orphan ,Iovitrum ,Gobi ,Selecta ,Iosciences ,Nnounce ,Completion ,Enrolment ,Dissolve ,Hase ,Study ,Valuating ,Hronic ,Refractory ,Out ,